ACIM
ESPR

Azimuth Capital Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Azimuth Capital Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.3K Hold
22,000
– – ﹤0.01% 298
2025
Q4 		$81.4K Hold
22,000
– – ﹤0.01% 305
2025
Q3 		$58.3K Hold
22,000
– – ﹤0.01% 296
2025
Q2 		$21.7K Hold
22,000
– – ﹤0.01% 297
2025
Q1 		$31.7K Hold
22,000
– – ﹤0.01% 300
2024
Q4 		$48.4K Hold
22,000
– – ﹤0.01% 298
2024
Q3 		$36.3K Hold
22,000
– – ﹤0.01% 301
2024
Q2 		$48.8K Hold
22,000
– – ﹤0.01% 302
2024
Q1 		$59K Hold
22,000
– – ﹤0.01% 306
2023
Q4 		$65.8K Buy
+22,000
New +$28.5K ﹤0.01% 300

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Azimuth Capital Investment Management's ESPR Position: Q1 2026 in Review

Azimuth Capital Investment Management held its Esperion Therapeutics (ESPR) position steady in Q1 2026 at 22,000 shares worth $60.3K. The position accounts for ﹤0.01% of the portfolio, ranked #298.

Azimuth Capital Investment Management first reported a position in ESPR in Q4 2023 and has held it in 10 quarters since. The position peaked at $81.4K in Q4 2025. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Azimuth Capital Investment Management held 22,000 shares of Esperion Therapeutics worth $60.3K as of Q1 2026.
  • Azimuth Capital Investment Management left its Esperion Therapeutics share count unchanged in Q1 2026.
  • Esperion Therapeutics made up ﹤0.01% of Azimuth Capital Investment Management's portfolio in Q1 2026, its #298 holding.
  • Azimuth Capital Investment Management first reported a position in Esperion Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Azimuth Capital Investment Management's Esperion Therapeutics position peaked at $81.4K in Q4 2025.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Azimuth Capital Investment Management's 13F filing for Q1 2026, filed 12 May 2026.